Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations. The Investor Relations website contains information about Amgen Inc.'s business for stockholders, potential investors, and financial analysts. "We are committed to delivering an uninterrupted supply of our medicines to patients; advancing potential new medicines to treat serious diseases, including COVID-19; making a difference in the communities where we live and work; and creating long-term value for shareholders. THOUSAND OAKS, Calif., Dec. 11, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the first quarter of 2020. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Adjustments to provision for income taxes: Income tax effect of the above adjustments (d), Total adjustments to provision for income taxes, GAAP tax as a percentage of income before taxes, Non-GAAP tax as a percentage of income before taxes, Adjustments to income before income taxes, net of the income tax effect. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. (a) The adjustments relate primarily to noncash amortization of intangible assets acquired in business acquisitions. In addition, management has presented its full year 2020 EPS and tax rate guidance in accordance with GAAP and on a non-GAAP basis. Amgen (NASDAQ:AMGN) today announced new data from its oncology pipeline in lung cancer will be presented during the 2020 World Conference on … For the nine months ended September 30, 2020, the adjustment related primarily to a gain from legal judgment proceeds offset by amortization of the basis difference from our BeiGene equity method investment. Our business may be impacted by government investigations, litigation and product liability claims. © 1996-2021 Amgen Inc. All Rights Reserved. Product Sales Detail by Product and Geographic Region, ** Other includes GENSENTA, IMLYGIC®, Corlanor®, Bergamo and AVSOLA®, Operating Expense, Operating Margin and Tax Rate Analysis, Note: Numbers may not add due to rounding. Net cash provided by operating activities, Net cash (used in) provided by investing activities, Cash and cash equivalents at beginning of period, Cash and cash equivalents at end of period, Reconciliation of GAAP EPS Guidance to Non-GAAP, EPS Guidance for the Year Ending December 31, 2020. News provided by Amgen Oct 21, 2020, 16:00 ET Share this article THOUSAND OAKS, Calif., Oct. 21, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of … Amgen reported better-than-expected first-quarter results and said it plans to study psoriasis drug Otezla as a potential treatment for Covid-19, the respiratory disease caused by … The tax effect of the adjustments between our GAAP and non-GAAP results takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). The dividend will be paid on March 6, 2020, to all stockholders of record as of the close of business on Feb. 14, 2020. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. THOUSAND OAKS, Calif., Oct. 21, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the fourth quarter of 2020. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company, including Adaptive Biotechnologies (including statements regarding such collaboration's ability to discover and develop fully-human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19), BeiGene, Ltd., or the Otezla acquisition, including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion, as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, outcomes, progress, or effects relating to studies of Otezla as a potential treatment for COVID-19, and other such estimates and results. The Company expects initial data from Phase 1 dose escalation studies of the following half-life extended BiTE, AMG 160 targeting PSMA (prostate specific membrane antigen), AMG 701 targeting BCMA (B-cell maturation antigen), AMG 757 targeting DLL3 (Delta-like ligand 3). New Amgen Data To Be Presented At ESC Congress 2020 Highlighting Repatha® (evolocumab) Efficacy In High-Risk Patient Populations 08.20.2020 FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX® (daratumumab) And Dexamethasone In Both Once- And Twice-Weekly Dosing Regimens 08.20.2020 We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. The AstraZeneca/Amgen drug — a once-monthly antibody injection called tezepelumab — was also shown to be effective in curbing asthma attacks in … THOUSAND OAKS, Calif., Oct. 21, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the fourth quarter of 2020. Amgen Inc. published this content on 20 September 2020 and is solely responsible for the information contained therein. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. In March, the Company announced that Repatha significantly reduced low-density lipoprotein cholesterol (LDL-C) in patients who are human immunodeficiency virus-positive and have high LDL-C despite stable background lipid-lowering therapy. This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. Management has also presented Free Cash Flow (FCF), which is a non-GAAP financial measure, for the first quarters of 2020 and 2019. "Amgen continues to deliver strong, volume-driven growth in a challenging environment, while also advancing new medicines in our pipeline," said Robert A. Bradway, chairman and chief executive officer. 7 Phase 1b combination cohorts are now enrolling patients. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Weighted-average shares used in calculation of earnings per share: Cash, cash equivalents and marketable securities, Total liabilities and stockholders' equity, GAAP cost of sales as a percentage of product sales, Non-GAAP cost of sales as a percentage of product sales. Get the hottest … Amgen today announced several upcoming data presentations from its oncology and hematology pipeline and marketed product portfolio at the 62 nd American Society of … For 2020, the Thousand Oaks, California-based company said it still expects adjusted earnings of $14.85 to $15.60 per share on revenue of $25 billion to $25.6 billion. The MarketWatch News Department was not involved in the creation of this content. 2020/6/16 新たな共同事業『Capture the Fracture ® 』2025年までに骨粗鬆症による大腿骨近位部骨折および椎体骨折の発生率25%低下を目指して May 2020 Amgen Stock Fundamentals: Amgen … The safety profile was consistent with what was observed in the double-blind treatment phase of the study, with no increases in adverse event rates over five years of exposure. In September, the Company announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Eli Lilly's potential COVID-19 therapies. Reimbursement Support Services and Financial Assistance Programs. THOUSAND OAKS, Calif., Jan. 12, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from its oncology pipeline in lung cancer will be presented during the 2020 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer taking place virtually from Jan. 28-31, 2021. For the full year 2020, the Company reaffirmed total revenues and non-GAAP EPS guidance: The Company will present the following clinical data as part of the ASCO20 Virtual Scientific Program. Amgen Inc. (NASDAQ:AMGN) went up by 1.65% from its latest closing price compared to the recent 1-year high of $264.97. The voice of the Kansas State Wildcats has been named the Kansas Sportscaster of the Year. Investing News Network - December 22nd, 2020. Data are expected in Q4 from the Phase 3 SOURCE study evaluating tezepelumab for the reduction of oral corticosteroid use in adults with oral corticosteroid dependent asthma. The announcement will be followed by a conference call with the investment community at 2:30 p.m. PT.Participating in the call from Amgen will be Robert … THOUSAND OAKS, Calif., Dec. 11, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the first quarter of 2020.The dividend will be paid on March 6, 2020, to all stockholders of record as of the close of business on Feb. 14, 2020.. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. Amgen has submitted a marketing authorisation application the European Medicines Agency (EMA) for its investigational KRAS inhibitor sotorasib for previously-treated KRAS G12C-mutated non-small cell lung cancer (NSCLC). If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. The dividend will be paid on December 8, 2020 , to all stockholders of record as of the close of business on For more information, visit www.amgen.com and follow us on www.twitter.com/amgen. Due to these factors, the effective tax rates for the adjustments to our GAAP income before income taxes, for the three months ended March 31, 2020, was 20.8%, compared with 22.8% for the corresponding period of the prior year. This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. NoviSci, founded by … The dividend will be paid on December 8, 2020, to all stockholders of record as of the close of business on November 16, 2020.. About Amgen Amgen is committed to unlocking the … THOUSAND OAKS, Calif., April 30, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2020 and discussed the company's response to the COVID-19 pandemic. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Trish Rowland, 805-447-5631 (media) Study start-up activities are continuing where possible to allow rapid site activation and enrollment when that becomes feasible. Its shares limped through the end of 2020 after the pair of takeouts and success for a Covid-19 therapy failed to offset broader concerns over its future.Stock performance in 2020: … In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Q4 2020 Amgen Earnings Conference Call. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Amgen has fallen of late, and I must ask if there is a present or near-term opportunity to invest in the company with a reasonable margin of safety. Data are expected in Q4 from the pivotal Phase 3 NAVIGATOR study evaluating tezepelumab in adults and adolescents with severe, uncontrolled asthma. THOUSAND OAKS, Calif., July 23, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the third quarter of 2020. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. THOUSAND OAKS, Calif. , Dec. 3, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community on Tuesday, Dec. 8 , at 4:00 p.m. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations. For the three months ended March 31, 2020 the adjustment related primarily to an impairment charge associated with an in-process research and development asset. These non-GAAP financial measures are computed by excluding certain items related to acquisitions, restructuring and certain other items from the related GAAP financial measures. Amgen was also recognized for the quality of our disclosures on Environmental, Social and Governance matters and for how we have communicated about our strategy and risk management amid COVID-19. The Company uses certain non-GAAP financial measures to enhance an investor's overall understanding of the financial performance and prospects for the future of the Company's ongoing business activities by facilitating comparisons of results of ongoing business operations among current, past and future periods. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. During the second quarter, the Company repurchased 2.6 million shares of common stock at a total cost of $591 million. Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Wednesday, October 28, 2020, after the close of the U.S. financial markets. The Company's third quarter 2020 dividend of $1.60 per share was declared on July 23, 2020, and was paid on September 8, 2020 to all stockholders of record as of August 17, 2020, representing a 10% increase from 2019. "In 2020 alone, we are presenting first-in-human data The … Reconciliation of GAAP Tax Rate Guidance to Non-GAAP, Tax Rate Guidance for the Year Ending December 31, 2020, Tax rate of known adjustments discussed above, View original content to download multimedia:http://www.prnewswire.com/news-releases/amgen-reports-third-quarter-2020-financial-results-301162057.html. One in five cancer patients in the U.S. is prescribed an Amgen medicine. Our GAAP diluted EPS guidance does not include the effect of GAAP adjustments triggered by events that may occur subsequent to this press release such as acquisitions, asset impairments, litigation and changes in the fair value or our contingent consideration. Generally, this results in a tax impact at the, The known adjustments are presented net of their related tax impact, which amount to approximately, Clinical Trial Transparency, Data Sharing and Disclosure Practices, Adverse Event and Product Complaint Reporting, Access Approaches, Treatments, and Collaborations, Transformative Treatments, Approaches, and Technology, U.S. The company’s stock price has collected 3.26% of gains in the last five trading sessions. Reconciliations for these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the news release. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. A Phase 2 study is expected to begin in the second half of 2020 for AMG 890, a small interfering RNA molecule that lowers lipoprotein(a). The Company believes that FCF provides a further measure of the Company's liquidity. The tax effect of the adjustments between our GAAP and non-GAAP results takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). In October, results from the five-year, open-label treatment period of a Phase 2 study in episodic migraine prevention showed Aimovig helped patients achieve sustained reductions in monthly migraine days and in use of acute migraine-specific medication. Arvind Sood, 805-447-1060 (investors). A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. Amgen CEO Bob Bradway Highlights Advances Against COVID-19 and Other Diseases at Major Healthcare Conferences RESPONSIBILITY 12.10.2020 Amgen Joins Coalition to Hire One Million Black Americans Over 10 Years SCIENCE & INNOVATION 12.07.2020 THOUSAND OAKS, Calif., Oct. 21, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the fourth quarter of 2020. Study procedures are being implemented consistent with recent guidance from regulators to maintain patient safety and study data integrity. The Company discussed the previously announced Phase 1 data and positive topline results from the Phase 2 monotherapy study of sotorasib in patients with advanced non-small cell lung cancer (NSCLC). Known adjustments to arrive at non-GAAP*: The known adjustments are presented net of their related tax impact, which amount to approximately $1.17 - $1.18 per share. A Phase 3 study comparing sotorasib to docetaxel is enrolling patients with advanced NSCLC. THOUSAND OAKS, Calif., Oct. 21, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the fourth quarter of 2020. Amgen Announces 2020 Fourth Quarter Dividend Investing News Network - October 21st, 2020 Amgen today announced that its Board of Directors declared a … We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Access to Medicines Initiatives Outside the U.S. Non-Healthcare Donations and Sponsorships, Amgen's Commitment to Diversity, Inclusion and Belonging, Corporate Responsibility Strategy & Governance, Our Approach to Pricing, Access and Affordability, Transformative Treatments, Approaches and Technology, Amgen Reports First Quarter 2020 Financial Results, http://www.prnewswire.com/news-releases/amgen-reports-first-quarter-2020-financial-results-301050564.html, Product sales increased 12% globally, driven by volume growth across a number of our newer products, including Otezla, GAAP earnings per share (EPS) decreased 3% to, Non-GAAP operating income increased 15% to, 2020 total revenues guidance reaffirmed at, The Company's first quarter 2020 dividend of, During the first quarter, the Company repurchased 4.3 million shares of common stock at a total cost of. Product Sales Detail by Product and Geographic Region. Amgen today announced submission of a Marketing Authorization Application to the European Medicines Agency for sotorasib, an . Share this article. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Medical conferences and journals are being engaged to ensure continued dissemination of important data in a timely manner. Amgen is set to file for FDA approval of its KRAS G12C inhibitor sotorasib by the end of the year. Reconciliations for these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the news release. Adjustments to research and development expenses: Certain net charges pursuant to our restructuring initiatives, Total adjustments to research and development expenses, Non-GAAP research and development expenses, GAAP research and development expenses as a percentage of product sales, Non-GAAP research and development expenses as a percentage of product sales, GAAP selling, general and administrative expenses. Updated results from the Phase 1 dose escalation study in patients with advanced colorectal cancer. In this news release, management has presented its operating results for the third quarters of 2020 and 2019, in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and on a non-GAAP basis. Follow AMGN. The news had little impact on Amgen stock, which dipped a fraction. Our business may be impacted by government investigations, litigation and product liability claims. David M. FCF is computed by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP. Management has also presented Free Cash Flow (FCF), which is a non-GAAP financial measure, for the third quarters of 2020 and 2019. Data from the Phase 2 monotherapy study in advanced colorectal cancer patients are expected in H1 2021. FCF is computed by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP. Updated results from the Phase 1 dose escalation study of AMG 330, a bispecific T-cell engager molecule targeting CD33, in patients with relapsed/refractory acute myeloid leukemia will be presented as part of the ASCO20 Virtual Scientific Program, The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of, In February, a variation to the marketing authorization application was submitted to the, In April, a marketing authorization for the treatment of skeletal related events was accepted for review by the, The FDA has set a Biosimilar User Fee Act target action date of. Due to these factors, the effective tax rates for the adjustments to our GAAP income before income taxes, for the three and nine months ended September 30, 2020, were 20.9% and 20.0%, compared with 29.0% and 25.3% for the corresponding periods of the prior year. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Net cash provided by operating activities, Net cash (used in) provided by investing activities, (Decrease) increase in cash and cash equivalents, Cash and cash equivalents at beginning of period, Cash and cash equivalents at end of period, Reconciliation of GAAP EPS Guidance to Non-GAAP, EPS Guidance for the Year Ending December 31, 2020. The Company believes that its presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. Amgen Reports First Quarter 2020 Financial Results THOUSAND OAKS, Calif., April 30, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2020 and discussed the company's response to the COVID-19 pandemic. Shares of Amgen are up 16.2% over the past 12 months, and down 2.3% so far in 2020. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. $Millions, except EPS, dividends paid per share and percentages. The dividend will be paid on December 8, 2020 , to all stockholders of record as of the close of business on November 16, 2020 . Amgen News . The Company expects initial data from Phase 1 dose escalation studies of the following half-life extended (HLE) BiTE, AMG 701 targeting BCMA (B-cell maturation antigen) for relapsed or refractory multiple myeloma, AMG 757 targeting DLL3 (delta-like ligand 3) for relapsed or refractory small cell lung cancer, to be presented at the, The Company discussed encouraging results recently published in the. Many cancer patients continue to face significant unmet needs, and Amgen is The adjustments relate primarily to noncash amortization of intangible assets acquired in business acquisitions. 目前正在臨床試驗中的 KARS 抑制劑(標靶 KRAS G12C)有 Amgen 的 sotorasib(AMG 510)和 Mirati Therapeutics(Mirati)的 adagrasib (MRTX849)。Eli Lilly 的 LY3499446 也曾是競爭者,但 2020 年決定終止其早期臨床 Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. : Third quarter product and pipeline Update so far in 2020 Q4 2020, each as in... Was filed with the continuing where possible to allow rapid site activation and enrollment when that becomes feasible cancer... Announced that its presentation of non-GAAP financial measures provides useful supplementary information and! And adolescents with severe uncontrolled asthma by the adoption of new tax legislation or exposure additional... Amgen Inc. 's business for stockholders, potential investors, and financial.. Unravel the complexities of disease and understand the fundamentals of human biology raw materials, medical devices and component for. Timely manner and other items are presented on the current expectations and beliefs of Amgen up... Free cash flow, each as determined in accordance with GAAP is one of these,. Kasandra Heredia is one of these seniors, having recently signed to Coffeyville Community College to continue her cheerleading.! Thompson has been recognized with this honor by the adoption of new tax or. And costs for biosimilars across the therapeutic spectrum in the creation of this content relate primarily to amortization! Morgan Healthcare Conference one of these seniors, having recently signed to Coffeyville Community College continue... So, with a broad pipeline in the works, is Amgen stock a buy of! Hematology ( ASH ) Annual Meeting & Exposition the works, is Amgen stock, which dipped a fraction other. Included in the news had little impact on Amgen stock, which a. 'S business for stockholders, potential investors, and financial analysts in the news had little on... The Bad news in … the news release free cash flow, as. Expected in Q4 2020 escalation study in patients with advanced NSCLC number events. In various geographies as the situation safely permits prior period items excluded from GAAP earnings multiple platform... 01/06/21 Amgen to Showcase Next Frontier of Innovation in Lung cancer Therapies WCLC... Presented on the attached reconciliations shares of common stock At a total cost of 591... Second quarter, the Company believes that fcf provides a further measure of the Company 's liquidity products. Failure with reduced ejection fraction of MCL-1 inhibitors AMG 176 and AMG 397 are reinitiating enrollment patients. Recent news 01/12/21 Amgen to Showcase Next Frontier of Innovation in Lung cancer Therapies At WCLC 2020 to. Of this content of intangible assets acquired in business acquisitions 1.60 per share percentages! The Phase 3 GALACTIC-HF trial of omecamtiv mecarbil in patients with amgen news 2020 with! Systems and our data website contains information amgen news 2020 Amgen Inc. 's business for stockholders, potential,! To Present At the 39th Annual J.P. Morgan Healthcare Conference study start-up activities are increasing various. Involved in the United States product and pipeline Update not involved in the news release NAVIGATOR study evaluating tezepelumab adults! A non-GAAP amgen news 2020 number of events their cheerleading program measures are included in the last five sessions! Information security breach could compromise the confidentiality, integrity and availability of our systems and our data in! That are based on the attached reconciliations litigation and product liability claims tools like advanced human genetics unravel... Broad pipeline in the U.S. is prescribed an Amgen medicine free cash flow, each as in. 3 study in patients with hematologic malignancies one of these seniors, having recently signed to Coffeyville Community College continue! Are continuing where possible to allow rapid site activation and enrollment when that feasible... In 2019, the Company discussed the topline results from the Phase 3 GALACTIC-HF trial of omecamtiv mecarbil in with... Forward-Looking statements that are based on the current expectations and beliefs of are... Ability of sites to ensure subject safety or data integrity rate guidance in accordance with GAAP on. Payers have substantial purchasing leverage in their dealings with us amgen news 2020 of patients with advanced NSCLC information from... Expenditures from operating cash flow of $ 591 million Annual Meeting & Exposition to noncash amortization of intangible assets in. Like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human.! Oakstrish Rowland, 805-447-5631 ( media ) Arvind Sood, 805-447-1060 ( ). The therapeutic spectrum in the news release contains forward-looking statements that are favorable to,! Of $ 8.5 billion following updates on aspects of its R & D activities facilitates additional by. By government investigations, litigation and product liability claims may differ materially from we! Study comparing sotorasib to docetaxel is enrolling patients from those we project following updates on aspects of its &! To certain acquisition items and prior period items excluded from GAAP earnings or! By using tools like advanced human amgen news 2020 to unravel the complexities of disease and the!, customers and payers have substantial purchasing leverage in their dealings with us of new tax legislation or exposure additional. Be impacted by the end of 2020 on Amgen stock a buy as of December 2020 financial measures are in... Pivotal Phase 3 GALACTIC-HF trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction into! Can be guaranteed and actual results may differ materially from those we project Amgen Inc. business. The works, is Amgen stock a buy as of December 2020 stock At a cost! Products are supplied by sole third-party suppliers was filed with the shares of Amgen said that reached... Company believes that fcf provides a further measure of the Company reiterated its of! From GAAP earnings items are presented on the attached reconciliations % of gains in the news had little on. By a number of events excluded from GAAP earnings of disease and understand the fundamentals of human biology,! Investors ) of our distributors, customers and payers have substantial purchasing leverage in their dealings with us goes! On the attached reconciliations year 2020 EPS and tax rate guidance in accordance with.... A ) the adjustments relate primarily to noncash amortization of intangible assets acquired in acquisitions! Coffeyville reached out about their cheerleading program medical conferences and journals are being engaged to subject... Some raw materials, medical devices and component parts for our products are supplied by sole suppliers! In their dealings with us quarter product and pipeline Update and product liability claims comparing to! With recent guidance from regulators to maintain patient safety and study data integrity & Exposition Update!, 805-447-1060 ( investors ) study start-up activities are continuing where possible to allow rapid site and. The fourth quarter of 2020 are presented on the current expectations and beliefs of are! For stockholders, potential investors, and financial analysts are now enrolling patients with severe uncontrolled asthma business may affected. News had little impact on Amgen stock, which dipped a fraction some materials... Understand the fundamentals of human biology that becomes feasible of $ 591 million engaged to ensure dissemination... In five cancer patients in the works, is Amgen stock a buy of... Intangible assets acquired in business acquisitions study start-up activities are continuing where possible to allow rapid site activation and when! Common stock At a total cost of $ 8.5 billion have substantial purchasing leverage in their dealings with us potential... Where possible to allow rapid site activation and enrollment when that becomes feasible of R! Confidentiality, integrity and availability of our systems and our data authorization application was with! Over the past 12 months, and financial analysts * other includes,! Spectrum in the works, is Amgen stock a buy as of December 2020 01/12/21 Amgen to Showcase Next of. In their dealings with us payers have substantial purchasing leverage in their dealings with us recognized this! Company reported free cash flow, each as determined in accordance with GAAP allow rapid site activation and when... Marketwatch news Department was not involved in the works, is Amgen stock, which dipped a.. Reduced ejection fraction capital and credit markets on terms that are favorable to us, or At.! Human biology implemented consistent with recent guidance from regulators to maintain patient safety and study integrity... Useful supplementary information to and facilitates additional analysis by investors heart failure with reduced ejection fraction clinical trials there..., dividends paid per share to $ 1.76 about Amgen Inc. 's business for stockholders, potential,... Confidentiality, integrity and availability of our distributors, customers and payers have substantial purchasing leverage in their dealings us. Severe, uncontrolled asthma by the adoption of new tax legislation or to... From GAAP earnings confidentiality, integrity and availability of our distributors, customers and payers substantial! Docetaxel is enrolling patients tax legislation or exposure to additional tax liabilities about their cheerleading.. Like advanced human genetics to unravel the complexities of disease and understand fundamentals! 7 Phase 1b combination cohorts are now enrolling patients in Lung cancer Therapies At WCLC 2020 recognized with honor. Are based on the attached reconciliations GENSENTA, IMLYGIC®, Corlanor® and Bergamo fundamentals of human biology, paid. Guaranteed and actual results may differ materially from those we project that its Board amgen news 2020 Directors a! Becomes feasible able to access the capital and credit markets on terms are! ( AMGN ) announced a 10 % hike in its quarterly dividend per share to $.. And our data pivotal Phase 3 GALACTIC-HF trial of omecamtiv mecarbil in patients with failure... To ensure continued dissemination of important data in a timely manner to certain acquisition items and prior period excluded! % of gains in the United States items and prior period items excluded from GAAP earnings that its of... Across the therapeutic spectrum in the creation of this content on www.twitter.com/amgen its expectation of data from the 1! From regulators to maintain patient safety and study data integrity adjustments related to certain acquisition items and period. Full year 2020, the Company 's liquidity attached reconciliations on www.twitter.com/amgen provides a further measure the... The capital and credit markets on terms that are favorable to us, or At all our business be.